Technologies related to NCI

Title
Treating Hypertension Using Erythropoietin and its Derivatives
Ref: E-158-2012 | Updated: Mar 9, 2018
High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research
Ref: E-136-2012 | Updated: Apr 24, 2018
Dual-Function Protein ATIA for Diagnostics and Therapeutics of Glioblastoma
Ref: E-178-2009 | Updated: May 30, 2018
Improved Personalized Cancer Immunotherapy
Ref: E-059-2013 | Updated: Mar 9, 2018
T Cell Receptors that Recognize the Tyrosinase Tumor Antigen
Ref: E-043-2009 | Updated: Jul 19, 2018
Human T Cell Receptors for Treating Cancer
Ref: E-269-2010 | Updated: May 4, 2018
Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness
Ref: E-269-2009 | Updated: Aug 31, 2016
Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity
Ref: E-034-2010 | Updated: Jul 19, 2018
High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment
Ref: E-198-2012 | Updated: Sep 6, 2016
Mouse Model for the Preclinical Study of Metastatic Disease
Ref: E-296-2012 | Updated: Jun 7, 2018
Use of Cucurbitacins and Withanolides for the Treatment of Cancer
Ref: E-050-2010 | Updated: Apr 9, 2018
Immunocompetent Mouse Model for Tracking Cancer Progression
Ref: E-173-2010 | Updated: Jun 18, 2018
Topical Antibiotic for Faster Wound Healing
Ref: E-294-2011 | Updated: Apr 23, 2018
Tumor Markers for Potentially Predicting Outcome of Anti-angiogenesis Therapy
Ref: E-096-2011 | Updated: Sep 8, 2016
Small-Molecule Inhibitors of Angiogenesis
Ref: E-263-2009 | Updated: May 4, 2018
Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C
Ref: E-217-2011 | Updated: Apr 20, 2018
Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)
Ref: E-158-2010 | Updated: Feb 5, 2018
Virus-Like Particles That Can Deliver Proteins and RNA
Ref: E-264-2011 | Updated: Sep 30, 2016
Biomarker for Predicting Taxane Chemotherapy Outcome
Ref: E-191-2009 | Updated: Aug 9, 2017
GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer
Ref: E-128-2009 | Updated: Apr 17, 2018
Phosphodiesterase as a target for cancer therapeutics
Ref: E-199-2010 | Updated: Sep 6, 2016
Mouse Xenograft Model for Mesothelioma
Ref: E-302-2009 | Updated: Mar 27, 2018
Detection of Novel Endocrine-Disrupting Chemicals in Water Supplies
Ref: E-269-2011 | Updated: Apr 20, 2016
Nanoparticles for the targeted treatment of infected cells
Ref: E-039-2012 | Updated: Jun 8, 2018
Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents
Ref: E-068-2011 | Updated: May 4, 2018
Modified POTE Peptides for Cancer Immunotherapy
Ref: E-003-2010 | Updated: Jun 19, 2018
Synergistic Combination Agent for Cancer Therapy
Ref: E-007-2011 | Updated: May 30, 2018
BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
Ref: E-009-2010 | Updated: May 30, 2018
Anti-Viral Compounds that Inhibit HIV Activity
Ref: E-081-2011 | Updated: Apr 20, 2018
Diagnostic for Cancer of the Adrenal Glands and Adrenal Cortex
Ref: E-135-2012 | Updated: Aug 31, 2016
Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy
Ref: E-013-2012 | Updated: Mar 6, 2017
Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters
Ref: E-132-2011 | Updated: Apr 17, 2018
Assay for Arf GTP-binding Proteins
Ref: E-198-2010 | Updated: Jul 19, 2018
Nitric Oxide-Releasing Polymers for Wound Healing
Ref: E-157-2012 | Updated: Sep 5, 2016
Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12
Ref: E-170-2009 | Updated: Aug 31, 2016
Software for Modeling Delivery and Penetration of Antibody Conjugates
Ref: E-060-2012 | Updated: Jun 7, 2018
Software for Accurate Segmentation of Cell Nuclei in Breast Tissue
Ref: E-106-2010 | Updated: Apr 18, 2018
Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic
Ref: E-133-2009 | Updated: Jul 19, 2018
New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines
Ref: E-089-2010 | Updated: Mar 9, 2018
Polypeptides for Stimulation of Immune Response (Adjuvants)
Ref: E-185-2008 | Updated: Jul 13, 2018
A Specialized Tissue Collection Device for the Preservation and Transportation of Needle Biopsies
Ref: E-128-2017 | Updated: Sep 5, 2018
T Cell Receptors Targeting p53 Hotspot Mutations and Methods of Isolating the Same
Ref: E-237-2017 | Updated: Sep 5, 2018
Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use
Ref: E-264-2015 | Updated: Dec 6, 2018
Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy
Ref: E-065-2017 | Updated: Sep 5, 2018
A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer
Ref: E-280-2016 | Updated: Aug 15, 2018
Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies
Ref: E-174-2012 | Updated: Aug 15, 2018
Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation
Ref: E-069-2018 | Updated: Aug 14, 2018
A Triple Combination HIV Microbicide
Ref: E-137-2016 | Updated: Aug 14, 2018
A Triple Combination HIV Microbicide
Ref: E-137-2016 | Updated: Aug 14, 2018
New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies
Ref: E-016-2018 | Updated: Aug 3, 2018
Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens
Ref: E-052-2013 | Updated: Aug 3, 2018
Anti-CD33 Chimeric Antigen Receptors for Treatment of Human Acute Myeloid Leukemia
Ref: E-097-2018 | Updated: Aug 2, 2018
Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors
Ref: E-106-2015 | Updated: Aug 2, 2018
Renal Selective Unsaturated Englerin Analogues
Ref: E-072-2014 | Updated: Aug 1, 2018
Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination
Ref: E-157-2000 | Updated: Aug 1, 2018
Improved HIV Vaccines Through Ras Activation
Ref: E-062-2014 | Updated: Aug 1, 2018
Scytovirin Domain 1 Related Polypeptides
Ref: E-180-2005 | Updated: Jul 27, 2018
Targeted RNA/DNA Nanoparticles with Single Stranded RNA Toeholds
Ref: E-078-2016 | Updated: Jul 27, 2018
Fusion Proteins as HIV-1 Entry Inhibitors
Ref: E-086-2015 | Updated: Jul 27, 2018
Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range
Ref: E-143-2017 | Updated: Jul 27, 2018
Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer
Ref: E-344-2013 | Updated: Jul 19, 2018
Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)
Ref: E-107-2017 | Updated: Jul 13, 2018
Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb
Ref: E-232-2015 | Updated: May 16, 2018
Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer
Ref: E-226-2014 | Updated: May 16, 2018
Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer
Ref: E-250-2014 | Updated: May 14, 2018
Polymeric Delivery Platform for Therapeutics
Ref: E-097-2017 | Updated: Dec 17, 2018
Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors
Ref: E-298-2016 | Updated: Feb 12, 2019
Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)
Ref: E-183-2017 | Updated: Mar 13, 2018
Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain
Ref: E-094-2013 | Updated: Apr 18, 2018
Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)
Ref: E-181-2009 | Updated: Feb 16, 2018
Cancer-reactive T cells from Peripheral Blood
Ref: E-149-2015 | Updated: Feb 16, 2018
A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis
Ref: E-058-2009 | Updated: Feb 16, 2018
IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
Ref: E-247-2015 | Updated: Jan 17, 2018
Conserved Elements Vaccine for HIV
Ref: E-132-2012 | Updated: Jun 28, 2019
Treatment Regimens for hetIL-15
Ref: E-126-2016 | Updated: Dec 6, 2017
Methods of Producing Effective T-cell Populations Using Akt Inhibitors
Ref: E-013-2016 | Updated: Dec 5, 2017
Schweinfurthins and Uses Thereof
Ref: E-183-2009 | Updated: Mar 20, 2018
Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2
Ref: E-216-2017 | Updated: Dec 4, 2017
T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy
Ref: E-175-2016 | Updated: Feb 7, 2018
NSAIDs that Assist the Treatment of Human Diseases
Ref: E-131-2011 | Updated: Feb 21, 2018
Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia
Ref: E-014-2017 | Updated: Oct 27, 2017
Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex
Ref: E-053-2015 | Updated: Apr 3, 2018
Combination Cancer Therapy with HDAC Inhibitors
Ref: E-065-2016 | Updated: Apr 3, 2018
Niclosamide for Treating Adrenocortical Cancer (ACC)
Ref: E-089-2016 | Updated: Jul 16, 2018
Combination Therapy for Prostate and Breast Cancer
Ref: E-257-2014 | Updated: Oct 27, 2017
Non-invasive Methods for Characterizing Adrenocortical Tumors
Ref: E-193-2015 | Updated: Mar 21, 2018
A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof
Ref: E-271-2014 | Updated: Mar 20, 2018
Clinical Outcome Predictors for Mantle Cell Lymphoma
Ref: E-131-2016 | Updated: Oct 25, 2017
A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays
Ref: E-001-2014 | Updated: Oct 23, 2017
Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles
Ref: E-277-2016 | Updated: Oct 23, 2017
Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors
Ref: E-115-2015 | Updated: Apr 18, 2017
Prognostic Biomarkers for Patients with Early Stage Lung Cancer
Ref: E-048-2012 | Updated: Apr 9, 2018
Vaccine for BK Polyomavirus-associated Infections in Transplant Recipients
Ref: E-168-2011 | Updated: Mar 21, 2018
Vectors to Increase Production Efficiency of Inducible Pluripotent Stem Cell (iPSC)
Ref: E-239-2010 | Updated: Mar 20, 2018
Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer
Ref: E-275-2014 | Updated: Oct 23, 2017
Compounds that Interfere with the Androgen Receptor Complex
Ref: E-162-2009 | Updated: Oct 23, 2017
Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy
Ref: E-078-2012 | Updated: Oct 11, 2017
Treating Cancer with Anti-Angiogenic Chimeric Antigen Receptors
Ref: E-205-2009 | Updated: Oct 11, 2017
Vaccines and Methods of Treating Drug-Resistant HIV-1 and Hepatitis B Viruses
Ref: E-137-2003 | Updated: Dec 10, 2018
Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases
Ref: E-159-2009 | Updated: Oct 10, 2017

Pages

Subscribe to Technologies related to NCI